
C4 Therapeutics Shelves BRAF Blocker, Goes All-In on Multiple Myeloma Drug
C4 Therapeutics will no longer pour money into its investigational BRAF inhibitor CFT1946, in the name of “strategic capital allocation,” the biotech announced Wednesday. Instead, C4 will focus its efforts and resources on its multiple myeloma drug …